Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results

DSpace/Manakin Repository

Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results

Citable link to this page

 

 
Title: Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results
Author: Weinrauch, Larry A; Liu, Jiankang; Claggett, Brian; Finn, Peter V; Weir, Matthew R; D’Elia, John A

Note: Order does not necessarily reflect citation order of authors.

Citation: Weinrauch, Larry A, Jiankang Liu, Brian Claggett, Peter V Finn, Matthew R Weir, and John A D’Elia. 2018. “Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results.” International Journal of Nephrology and Renovascular Disease 11 (1): 1-7. doi:10.2147/IJNRD.S148517. http://dx.doi.org/10.2147/IJNRD.S148517.
Full Text & Related Files:
Abstract: Introduction: Single-center and observational studies have suggested that calcium channel blocking agents may decrease the expression of sepsis in individual populations. In the renal transplant population, a role for calcium channel blockers in allograft protection and in prevention of sepsis has been postulated. We hypothesized that any important survival benefit or risk related to chronic use of calcium channel blocking agents should be discernable through an analysis of a large database of stable recipients of renal allografts who had enrolled in a large international trial. Methods: A retrospective analysis of 4,110 renal transplant recipients who enrolled in the international Folic Acid for Vascular Outcome Reduction in Transplantation trial between 2002 and 2007 and were followed until 2010 was undertaken comparing cohorts (FAVORIT) of patients either taking (n=1,436) or not taking (n=2,674) calcium channel blocking medications. The endpoint was all-cause mortality (cardiovascular, noncardiovascular mortality, or unknown). Results were adjusted for country, age, race, sex, smoker, systolic blood pressure, diabetes mellitus, low-density lipoprotein, and chronic kidney disease status. Results: There were no statistically significant differences in incidence rates of cardiovascular, noncardiovascular, and all-cause mortality between patients taking or not taking calcium channel blocking medications. Conclusion: Although physiologic reasoning and small series results suggest a benefit for calcium channel blocking agents for allograft protection and sepsis prevention in immunosuppressed patients, we find no clear survival benefit in a large international renal transplant trial.
Published Version: doi:10.2147/IJNRD.S148517
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743121/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34868737
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters